1. Antitumor effect of the combination of 14.18-IL-2 IC and anti–CTLA-4.
Antitumor effect of the combination of IL-2 IC and anti–CTLA-4. (A and B) B78 melanoma cells were injected s.c. into C57BL/6 mice (day 0) IL-2 IC (5 μg per mouse) was injected IT daily on days 7–11. Anti–CTLA-4 (200 μg per mouse) was injected i.p. on days 7, 9, 11, 14, 16, and 18. Data are shown as means ± SEM of tumor volumes (A) and survival (B) of five mice per group. (A) Differences between a combined treatment versus separate treatment groups are shown. (C and D) Role of T cells. B78 melanoma cells were injected s.c. into C57BL/6 (C) and Nude (D) mice on day IL-2 IC (5 μg) was given IT on days 6–10. Anti–CTLA-4 (200 μg) was given i.p. on days 6, 8, and 10. Data shown are means ± SEM of four to five mice per group. (E) Effect against advanced tumors. B78 cells were injected s.c. into C57BL/6 mice (day 0). Mice received IL-2 IC IT (5 μg) on days 12–16 and anti–CTLA-4 i.p. on days 12, 14, 16, 19, 26, and 33. Data shown are means ± SEM of four to five mice per group. Differences between the control versus treatment groups are shown. Statistical differences are indicated for the last day on the graph. *p < 0.05, **p < 0.01, ***p <
Alexander L. Rakhmilevich et al. J Immunol 2017;198:
Copyright © 2017 by The American Association of Immunologists, Inc.